WVP
SLNO

Worth Venture Partners’s Soleno Therapeutics SLNO Stock Holding History

Worth Venture Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-90,858
Closed -$390K – 188
2023
Q2 		$390K Sell
90,858
-13,055
-13% -$56.1K 0.21% 82
2023
Q1 		$222K Hold
103,913
– – 0.11% 122
2022
Q4 		$206K Sell
103,913
-1,600
-2% -$1.99K 0.12% 110
2022
Q3 		$176K Sell
105,513
-1
-0% -$2 0.11% 113
2022
Q2 		$301K Sell
105,514
-7,275
-6% -$20.1K 0.18% 90
2022
Q1 		$377K Buy
+112,789
New +$584K 0.17% 93

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Worth Venture Partners's SLNO Position: Q3 2023 in Review

Worth Venture Partners sold out of Soleno Therapeutics (SLNO) in Q3 2023, closing a stake of 90,858 shares — an estimated $390K sold.

Worth Venture Partners first reported a position in SLNO in Q1 2022 and held it in 6 quarters. The position peaked at $390K in Q2 2023. 54 funds tracked by Wall St. Rank hold SLNO as of Q3 2023.

  • Worth Venture Partners reported no remaining Soleno Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Worth Venture Partners sold 90,858 Soleno Therapeutics shares in Q3 2023, an estimated $390K.
  • Worth Venture Partners first reported a position in Soleno Therapeutics in Q1 2022 and held it in 6 quarters.
  • Worth Venture Partners's Soleno Therapeutics position peaked at $390K in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2023.

Based on Worth Venture Partners's 13F filing for Q3 2023, filed 15 Nov 2023.